A descriptive analytic and observational study was conducted to determine whether type II diabetes mellitus with incipient nephropathy have significant increased risk factors for cardiovascular disease than those without nephropathy. Thirty four patients with type II diabetes mellitus (non insulin dependent diabetes mellitus) treated in the Department of Internal Medicine Dr. Sardjito General H…
A study was conducted to compare indapamide with captopril in preventing the progress of diabetic nephropaty. Each group was consist of 25 NIDDM patients. The study showed that both drug were equaly effective in decreasing albumin exretion rate. Both drugs did not change lipid electrolit profile. It is concluded that indapamide could be used as an alternatif to captopril.
It is estimated more than 50 percent of diabetic patients are dyslipidemic, this prevalence is higher in those with poorly controlled diabetic. Glycemic control may improve the lipid serum profiles, eventhough glycemic control may improve the lipid serum profiles, eventhough glycemic control by it self is not sufficient to control diabetic dyslipidemia. There is very little publications to cont…
Fibrinogen and antithrombin-II (ATIII) are the two components of hypercoagulable states. It has been known that Diabetes Mellitus (DM) is associated with alteration of hypercoagulable states secondary. To study the fibrinogen and ATIII levels in NIDDM patients, factors influencing is abnormalities and the cerrection with retinopathy a cross sectional study among 30 NIDDM patients at Diabetes Ou…
To determine the relationship between some aggravating factors namely dyslipidemia, diabetic retinopathy, and microalbuminuria and Blood Pressure (BP) in Non-Insulin Dependent Diabetes Mellitus (NIDDM) patients we screened NIDDM patients for BP, lipid profile, and the presence of retinopathy and microalbuminuria at in-patient department of Internal Medicine Sardjito General Hospital, Yogyakarta…
Arround 10 percent NIDDM patients will develope secondary failure every year. Acarbose could lower the absorbtion of glucose from the intestines. The aim of the study is to evaluate the benefit of acorbose as adjuvant treatment to NIDDM with secondary failure to glibenclamide. Patients were secondary failure to glibenclamide include to the study. The study was done in two phases. First phase: t…